Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
0.4859
+0.0267 (5.81%)
Jul 28, 2026, 4:00 PM EDT - Market closed

Heron Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
150.71154.9144.29127.04107.6786.35
Revenue Growth
1.48%7.36%13.57%17.99%24.70%-2.59%
Gross Profit
107.18113.56105.6461.9452.840.33
Operating Income
-10.46-2.54-11.53-110.62-174.66-217.83
Net Income
-10.49-20.2-13.58-110.56-182.02-220.68
Earnings Per Share
-0.18-0.12-0.09-0.80-1.67-2.24
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
44.7846.6359.2880.4184.85157.58
Total Debt
141.63140.64177.76179.63157.48159.5
Net Cash (Debt)
-96.85-94.01-118.48-99.22-72.63-1.92
Net Cash Growth
------
Net Cash Per Share
-0.55-0.56-0.78-0.72-0.67-0.02

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-20.26-27.59-22.53-58.79-146.91-203.35
Capital Expenditures
-0.6-0.32-1.71-1.55-1.83-3.02
Free Cash Flow
-20.86-27.91-24.24-60.33-148.74-206.38
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
71.12%73.31%73.21%48.75%49.04%46.70%
Operating Margin
-6.94%-1.64%-7.99%-87.07%-162.21%-252.27%
Pretax Margin
-6.94%-13.04%-9.41%-87.02%-169.05%-255.58%
Profit Margin
-6.94%-13.04%-9.41%-87.02%-169.05%-255.58%
FCF Margin
-13.84%-18.02%-16.80%-47.49%-138.14%-239.01%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-209.09----
PS Ratio
0.611.581.612.012.7710.79